7.30-17.30 EST | 4.30-14.30 PST

7:30 am Online Networking Coffee

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards.

Priming Both the Innate and Adaptive Immunity Pathways

7:50 am Organizer’s Opening Remarks

7:55 am Chair’s Opening Remarks

  • Shannon Morris Vice President of Clinical Development , Istari Oncology

8:00 am Role of Innate Immune Signals in Antitumor Immunity – What do we Know Today?

  • Art Krieg Founder, Chief Scientific Officer, Checkmate Pharmaceuticals

Synopsis

  • Lifting the innate immune barriers to anti-tumor immunity
  • Orchestrating T-cell recruitment and infiltration at the tumor site by targeting cellular components (e.g. myeloid lineage) component of the innate immune system.
  • Comparing the different innate immune cells – which one to choose?
  • What are the differences, in terms of human immune responses, that stimulating different immune targets can lead to?
  • Comparing TLR9 vs TLR8 vs STING vs RIG-I

8:25 am Combination Systemic Therapy with a Multiple TLR Agonist Safely Eradicates Established Tumors with Induction of Innate and Adaptive Immunological Memory

  • Michael Newman President & Chief Executive Officer, Decoy Biosystems

Synopsis

  • Decoy Biosystems is developing a new and improved systemicallyadministered version of Coley’s Toxins (killed, non-pathogenic, Gramnegative bacteria) that exhibits single agent activity and also synergizes with approved agents to safely eradicate established, solid tumors with induction of innate and adaptive immunological memory.
  • Decoy bacteria are also active as a single agent in pre-clinical models of chronic human HBV and HIV infection.

8:50 am Speaker Q&A

  • Art Krieg Founder, Chief Scientific Officer, Checkmate Pharmaceuticals
  • Michael Newman President & Chief Executive Officer, Decoy Biosystems

9:00 am Panel Discussion: Rationale, Progress and Development of STING & TLR-Targeted Therapies

Synopsis

  • Harnessing the innate immune system and local immunological microenvironment
  • Shaping tumor immunogenicity
  • Priming responses to checkpoint blockade – the relative importance of these pathways in regulating antitumor immunity and responsiveness to checkpoint blockade (PD-1, PD-L1, CTLA-4 inhibitors)
  • Identifying clinical indications that are sensitive to innate immune stimulatory approaches (e.g. beyond melanoma)
  • Challenges and opportunities in the clinical setting

9:40 am Virtual Speed Networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into the speed networking session. This is your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

10:04 am Organizer’s Opening Remarks

10:05 am A unique holistic oncology drug development platform using fresh human tumor tissue which retains the tumor microenvironment including ECM, immune and tumor cells.

  • Bonnie Philips Associate Director of Translational Applications, Nilogen Oncosystems

Synopsis

  •  Study the impact of singlet and combination therapies on STING and TLRs in the same patient tumor tissue – published data to be presented.
  • Study Penetration, Phagocytosis, Tumor Cell Killing using Confocal Microscopy, and Cytokine release whilst quantifying the immune profile and cellular proliferation using Flow Cytometry, and proteogenomics using Nanostring , scRNAseq and CITE-seq.
  • One living tissue platform for use with all therapeutics – chemotherapies, monoclonal antibodies, bi and tri-specifics, ADCs, ADCCs, ACTs and Oncolytic Viruses.

Enhancing Administration & Delivery of Therapies for Safe & Effective Clinical Outcomes

10:35 am Opening remarks from chair person

  • Shannon Morris Vice President of Clinical Development , Istari Oncology

10:40 am Intratumoral (IT) Immunotherapies. Current Status & Ongoing Clincial Trials

  • Sonia Macia Director, Medical, Highlight Therapeutics

Synopsis

  • Differences among IT therapies. Mechanisms of action. Number and locations of lesions to be injected
  • Challenges we are facing. Are response criteria accurate? itRECIST. Exploratory objectives in clinical research to be implemented
  • Number of cycles to be administered. How to handle different posologies and treatment combinations

11:05 am Tissue-Targeted TLR7 Agonists for Cancer Immunotherapy

  • Andrew Miller Vice President of Immunology and Operations, Apros Therapeutics

Synopsis

  • Overview of various targeting approaches to localize TLR7 agonists to specific tissues for an improved therapeutic window (beyond intratumoral)
  • Highlights of preclinical data around our most advanced program now in the clinic, which is an orally administered liver/GI-targeted TLR7 agonist for liver/GI malignancies
  • Highlights of preclinical data on targeted TLR7 agonists in infectious disease

11:30 am Speaker Q&A

  • Sonia Macia Director, Medical, Highlight Therapeutics
  • Andrew Miller Vice President of Immunology and Operations, Apros Therapeutics

11:40 am Targeted Immune Cell Activation by Systemic Delivery of Toll- Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity

  • Hong Wan Chief Executive Officer, Tallac Therapeutics

Synopsis

  • Novel therapies engaging both innate and adaptive immune responses may engender durable anti-tumor immunity
  • Activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides promotes innate inflammatory responses and induction of adaptive immunity
  • We developed a novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation via systemic administration
  • We evaluated various TRAAC approaches targeting either immune cell receptors or tumor specific antigens, demonstrating robust immune modulation and potent single agent anti-tumor activity in pre-clinical settings

12:05 pm Intratumoral treatment with CV8102 , an RNA based immunomodulator activating TLR7/8 and Rig I

  • Ulrike Gnad-Vogt Senior Vice President Oncology & Translational Medicine, Chief Development Officer ad interim, CureVac

Synopsis

  • Intratumoral CV8102 showed antitumor efficacy as single agent and
    combination with anti PD1 antibodies in preclinical models
  • CV8102 as single agent and in combination with anti PD1 antibody is
    being investigated in a phase I trial in patients with solid tumors
  • Preliminary data on safety and efficacy will be presented

12:30 pm STACT: A Novel Therapeutic Platform that Delivers Combination STING Immunotherapy to Tumor Resident Myeloid Cells After IV Dosing

  • Laura Glickman Vice President, Research & Co- Founder, Actym Therapeutics

Synopsis

  • In a metastatic disease setting, systemically-administered immunotherapies will be required to promote proper T-cell infiltration in immune-excluded tumors
  • Many agents are in development to properly inflame these tumors, including STING agonists, co-stimulatory receptor agonists and type I/II cytokines, but are too toxic or ineffective when systemically administered
  • Here we describe a microbial-based immunotherapy platform, STACT (S.Typhimurium Attenuated Cancer Therapy), that enables IV dosing of multiplexed immunomodulatory payloads in a single therapeutic composition and induces durable anti-tumor immunity in preclinical models of T-cell excluded, checkpoint refractory solid tumors

12:55 pm Speaker Q&A

  • Hong Wan Chief Executive Officer, Tallac Therapeutics
  • Laura Glickman Vice President, Research & Co- Founder, Actym Therapeutics
  • Ulrike Gnad-Vogt Senior Vice President Oncology & Translational Medicine, Chief Development Officer ad interim, CureVac

1:10 pm Online Networking Lunch

Enhancing Administration and Delivery for Safe and Effective Clinical Outcome

1:40 pm Opening remarks from chair person

  • Marc Damelin Vice President & Head of Biology , Mersana Therapeutics

1:45 pm PRTX007, A Novel Orally Administered TLR7 Agonist Prodrug for the Treatment of Cancer

  • James Appleman Senior Vice President R&D & Chief Scientific Officer, Primmune Therapeutics

Synopsis

  • Unique pharmacology elicited by PRTX007 distinguishes this from other TLR7 agonists
  • This clinical candidate is the result of an extensive medicinal chemistry program
  • Cellular pharmacology and PK and PD of PRTX007 in animal models will be described

2:10 pm Design & Development of a Systemic, Small Molecule STING Agonist: Tailoring Drug Properties and Dosing Paradigm to Optimize Therapeutic Index for the Treatment of Cancer Patients

Synopsis

  • Molecular design
  • Pharmacology of STING agonism and type I IFN driven anti-tumor immunity
  • Biomarker and translation

2:35 pm Speaker Q&A

Developing an Innate Immune Modulator Capable of Delivering Clinical Responses in Solid Tumors

2:45 pm Opening remarks from chair person

  • Marc Damelin Vice President & Head of Biology , Mersana Therapeutics

2:50 pm New Generation of STING Agonists – Development & Characterization of a Novel Series of Systemic Immunomodulators with Improved Potency

  • Krysztof Brzozka Chief Scientific Officer & Executive Vice President, Ryvu Therapeutics

Synopsis

  • New generation Ryvu STING agonists are strong binders of human STING protein and show high cellular potency of inducing cytokine production in human immune cells at low nM range
  • The compounds are characterized by drug-like properties and high in vitro potency irrespective of the natural human STING variant and the chemotype is amenable for linking technologies allowing targeted delivery
  • High cellular potency of Ryvu series translates into efficacy observed in vivo, where systemic intravenous administration leads to complete tumor regressions in mouse syngeneic models

3:15 pm Second Generation STING Agonist SB11285: Improving Checkpoint Inhibitor Outcomes

Synopsis

  • The STING pathway can induce the activation of tumor-resident Antigen Presenting Cells (APCs) and trafficking of CD8+ T cells to the tumor in preclinical models.
  • Survival and local tumor shrinkage in syngeneic models were significantly enhanced when SB11285 was administered intravenously with anti-CTLA antibody or anti-PD-1 antibody, suggesting synergistic activity with concomitant STING activation.
  • Phase 1a/1b dose-escalation study of intravenously administered SB 11285 as monotherapy and in combination with atezolizumab is on-going in patients with advanced solid tumors.

 

3:40 pm Speaker Q&A

3:50 pm Online Networking Break

Progress in Targeting Innate Immunity in Combination Immunotherapies

4:05 pm Opening remarks from chair

  • Marc Damelin Vice President & Head of Biology , Mersana Therapeutics

4:10 pm Development of MRx0518 – a novel Live Biotherapeutic TLR5 agonist for the treatment of solid tumors

Synopsis

  • MRx0518 is a strain of Enterococcus gallinarum that demonstrated anti-tumor activity in preclinical animal models, shown to be mediated by TLR5 engagement on gut epithelia cells and induction/activation of tumoral immune cell subsets and systemic immune cells
  •  MRx0518 has now demonstrated single agent immunomodulation of the tumor microenvironment and the peripheral immune system in patients
  • Clinical benefit has been observed in PD-1 checkpoint refractory patients when re-challenged with MRx0518 in combination with KEYTRUDA (R) (pembrolizumab)

4:40 pm Mode of Action in STING Agonists to Identify Rational Combinations

  • Sebastian Carotta Scientific Director, Cancer Cell Signalling, Boehringer Ingelheim

Synopsis

  • STING pathway agonists are highly attractive for cancer immunotherapy as they are potent innate immune cell activators
  • For successful STING therapy, several challenges need to be addressed: bell-shaped dose-efficacy relationship, potentially limited numbers of injections possible, in cold tumor STING Ag treatment might not be sufficient to induce strong enough CD8+ T cell infiltration for synergy with a-PD1 Therapy
  • Rational combinations with STING Ag at the beginning of cancer immunity cycle (induction of cancer cell death resulting in Ag and DAMP release) should translate into better efficacy in patients with cold tumours
  • Rational combinations with STING Agonists will be discussed

5:05 pm Speaker Q&A

5:15 pm Title to be Confirmed

5:40 pm Turning Up The Heat In Melanoma: Synergies between TLR9 Agonists and Anti-PD-1

6:05 pm Speaker Q&A

6:15 pm Closing remarks

  • Marc Damelin Vice President & Head of Biology , Mersana Therapeutics

6:25 pm End of day